secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2022-05-13T23:59:59+00:00
Accession:  0000944809-22-000029
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO Health acquires ModeX Therapeutics for $300M in stock; appoints Dr. Zerhouni as President
--------------------------------------------------------------------------------

- Merger consideration of $300M paid via 89,907,310 shares of OPKO common stock.
- Dr. Elias Zerhouni appointed President and Vice Chairman; Dr. Gary Nabel named Chief Innovation Officer and director.
- Alexis Borisy appointed to board; receives 312,612 restricted shares and options.
- Frost Gamma Investments Trust and holders of ~88% of consideration shares subject to 4-year lockup.
- Zerhouni employment: $900K base, target bonus ≥50%; Nabel: $750K base, target bonus ≥50%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000094480922000029/0000944809-22-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000094480922000029/opk-20220509.htm
  HTML page:      https://secwatch.observer/filing/0000944809-22-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer